RxDoctor Payments Data

James Hurley, MD

Cardiovascular Disease · Texarkana, TXNPI 1366485237

Payments from drug & device makers

$1,726in general payments, 2019–2025

Across 100 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$565
  • E.r. Squibb & Sons, L.L.C.$350
  • Pfizer$242
  • Johnson & Johnson$208
  • Merck$74
  • Biosense Webster, Inc.$49
  • plus $238 from 11 others

What the payments were for

  • Food & beverage$1,726100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,726 in reported general payments places this provider in the 30th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$247,153
Medicare patients
952
Services billed
3,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban412$425,228
EntrestoSacubitril/Valsartan71$76,153
XareltoRivaroxaban18$20,706
Repatha SureclickEvolocumab17$12,696
Potassium Chloride402$6,747
Ranolazine ErRanolazine85$5,289
Minoxidil103$3,239
Flecainide Acetate108$2,995
Losartan Potassium191$2,262
Isosorbide Mononitrate ErIsosorbide Mononitrate206$2,249
Furosemide472$2,147
Metoprolol Succinate146$1,897
Atorvastatin Calcium202$1,727
ClopidogrelClopidogrel Bisulfate194$1,609
Metoprolol Tartrate248$1,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$242$425,228412 claims
NovartisEntresto$565$76,15371 claims
Johnson & JohnsonXarelto$208$20,70618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Texarkana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →